New drug duo takes on Hard-to-Treat cancers

NCT ID NCT05765851

Recruiting now Disease control Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 5 times

Summary

This early-phase trial is testing a new drug called DS-1103a combined with an existing cancer drug, Enhertu, in people with advanced solid tumors that have a specific genetic marker (HER2). The study aims to find a safe dose and see if the combination shrinks tumors. About 108 adults with advanced or metastatic cancer are being enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DS-1103a combined with trastuzumab deruxtecan (T-DXd, Enhertu)
What this could lead to: If successful, this could point toward a new combination treatment for advanced solid tumors that have HER2 mutations or overexpression.
What could go wrong: This is a very early Phase 1 trial with only 108 participants, so safety and dosing are still being figured out. Many early-stage cancer trials do not lead to approved treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Centre Léon Bérard
ACTIVE_NOT_RECRUITING

Lyon, Rhone, 69373, France
Florida Cancer Specialists
RECRUITING

Sarasota, Florida, 34232, United States
Hospital Universitari Vall d'Hebron
RECRUITING

Barcelona, 8035, Spain
Lifespan Cancer Institute
RECRUITING

Providence, Rhode Island, 02903, United States
NEXT Oncology
RECRUITING

Fairfax, Virginia, 22031, United States
Oncopole - Institut Claudius Regaud
ACTIVE_NOT_RECRUITING

Toulouse, Haute Garonne, 31059, France
Princess Margaret Cancer Centre, University Health Network
RECRUITING

Toronto, M5G 2M9, Canada
University of Utah
RECRUITING

Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.